UROTHELIAL CANCER

This study is for people with metastatic urothelial carcinoma, a type of advanced bladder cancer. It tests combinations of three drugs—sacituzumab govitecan, enfortumab vedotin, and pembrolizumab—to find safe doses and see if they shrink tumors. About 106 participants will join t…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 355 adults …

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors.

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…

This study tests a new drug combination (datopotamab deruxtecan plus chemotherapy) against standard chemotherapy for people with advanced bladder cancer that has worsened after initial treatment. About 630 adults will participate to see if the new combo shrinks tumors or delays c…

This early-stage study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find the safest dose and check for side effects. Participants have cancers like head and neck, lung, breast, or ovarian cancer that haven't r…

This early-phase study tests two experimental drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination is safe and helps the immune system f…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 480 adults will take part in this first human trial.

This study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing surgery to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will get either the drug combo or standard chemoradi…

This study tests a new drug, izalontamab brengitecan, against standard chemotherapy for people with advanced bladder cancer that got worse after immunotherapy. About 470 adults will be randomly assigned to receive either the new drug or chemo. The goal is to see if the new drug c…

This study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…

This study tests a two-drug treatment (gemcitabine and Jelmyto) for a type of high-risk urinary tract cancer. The goal is to destroy the tumor while keeping the kidney intact, avoiding the standard surgery that removes the kidney. About 28 adults with non-invasive, high-grade can…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study is testing whether analyzing DNA and proteins in urine can help detect urothelial cancers of the bladder and kidney. Researchers will collect urine samples from 500 adults—some with known or suspected cancer and some healthy controls—to see if this non-invasive approac…

This early study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. The main goal is to check if the drug is safe and how it moves through the body, …

This study is observing about 200 adults in South Korea with advanced bladder cancer who are already prescribed PADCEV. Researchers will track side effects and how well the cancer responds over about one year. No new treatments are given—only medical records are reviewed.

This study tracks 1,100 adults with common and rare urinary tract cancers (like bladder, kidney, or testicular cancer) over their lifetime. Researchers collect medical records, blood, urine, and tumor samples to understand how these cancers behave and respond to treatment. The go…

This study collects blood, urine, saliva, and tumor tissue from 500 adults with or at risk for urothelial cancer (bladder, ureter, urethra). Researchers will analyze the DNA and other molecular features of these samples to understand what causes the cancer and how it responds to …

This study follows about 80 people with advanced bladder cancer who are getting a new two-drug treatment (enfortumab vedotin and pembrolizumab). The goal is to see how often nerve damage (peripheral neuropathy) occurs and how it affects their daily life. Researchers will track sy…